Shenogen Pharma, a company developing mAbs that target the ER-alpha 36 receptor to treat cancer, has signed a contract with ShangPharma Corporation for development work. The emphasis on mAbs represents a departure for Shenogen, which previously sought to blend Western pharma with its knowledge of TCM. The company’s lead molecule, SNG-162, is a TCM that targets an Estrogen Receptor (ER) variant discovered by one of Shenogen’s founders. Shenogen Pharma’s science was so impressive it won a “Most Promising Company” award at the Shanghai ChinaBio® Investor Forum held in 2008. More details....

Stock Symbol: (NYSE: SHP)     Share this with colleagues: